Iron(II) spin crossover complexes of tetradentate Schiff-bases: tuning T1/2 by choice of formyl-heterocycle component.

Four new tetradentate Schiff-base ligands were prepared in situ from the 1 : 2 condensation of 1,3-diaminopropane and either 2-thiazolecarboxaldehyde (L2thiazole), 4-thiazolecarboxaldehyde (L4thiazole), 4-oxazolecarboxaldehyde (L4oxazole), or 5-bromopyridine-2-aldehyde (L5Br-pyridine), and complexed with [Fe(NCS)2(pyridine)4] to give four monometallic FeII complexes, [Fe(Lheterocycle)(NCS)2]. Structural characterisation shows the expected octahedral FeII centres in all cases, with Lheterocycle occupying the equatorial plane and the two thiocyanate ligands trans to each other, resulting in an N6 coordination sphere. Solid state magnetic measurements showed that the two complexes with the thiazole-based ligands exhibit the beginning of a spin transition above 300 K, with T1/2 = 350 K for [Fe(L4thiazole)(NCS)2] and 400 K for [Fe(L2thiazole)(NCS)2], whereas the 4-oxazole-based ligand gives [Fe(L4oxazole)(NCS)2] which remains high spin at all measured temperatures (50-400 K). Interestingly, [Fe(L5Br-pyridine)(NCS)2] crystallised as two solvent-free polymorphs: magnetic measurements on samples with both polymorphs present showed a two step SCO with an abrupt transition at T1/2 = 245 K assigned to the transition in polymorph A (as this was also seen in a sample of pure polymorph A), and a gradual transition at T1/2 = 304 K assigned to polymorph B. These findings show that the order of increasing ligand field strength for these heterocycles is 4-oxazole ≪ 5Br-pyridine < 4-thiazole < 2-thiazole.

Ironsand (Titanomagnetite-Titanohematite): Chemistry, Magnetic Properties and Direct Applications for Wireless Power Transfer.

Ironsand is an abundant and inexpensive magnetic mineral resource. However, the magnetic properties of unprocessed ironsand are often inadequate for any practical applications. In this work, the applicability of ironsand for use as a component in a soft magnetic composite for large-scale inductive power transfer applications was investigated. After magnetic separation, the chemical, structural and magnetic properties of ironsand sourced from different locations were compared. Differences observed in the DC magnetic properties were consistent with changes in the chemical compositions obtained from X-ray Absorption Near-Edge Spectroscopy (XANES), which suggests varying the titanohematite to titanomagnetite content. Increased content in titanomagnetite and magnetic permeability correlated well with the total Fe content in the materials. The best-performing ironsand with the highest permeability and lowest core losses was used alongside Mn,Zn-Ferrite particles (ranging from ∼100 µm to 2 mm) to fabricate toroid cores with varying magnetic material loading. It was shown that ironsand can be used to replace up to 15 wt.% of the magnetic materials with minimal impact on the composite magnetic performance, thus reducing the cost. Ironsand was also used as a supporting material in a single-rail wireless power transfer system, effectively increasing the power transfer, demonstrating potential applications to reduce flux leakage.

Corrigendum: Electrospun, Oriented, Ferromagnetic Ni 1-x Fe x Nanofibers.

[This corrects the article DOI: 10.3389/fchem.2020.00047.].

Electrospun, Oriented, Ferromagnetic Ni 1-x Fe x Nanofibers.

Electrospinning has been used to fabricate ferromagnetic Ni0.47Fe0.53 nanofiber mats that were composed of individual, orientated Ni0.47Fe0.53 nanofibers. The key steps were processing a polyvinylpyrrolidone nanofiber template containing ferric nitrate and nickel acetate metal precursors in Ar at 300°C and then 95% Ar: 5% H2 at 600°C. The Ni0.47Fe0.53 fibers were nanostructured and contained Ni0.47Fe0.53 nanocrystals with average diameters of ~14 nm. The Ni0.47Fe0.53 ferromagnetic mats had a high saturation magnetic moment per formula unit that was comparable to those reported in other studies of nanostructured Ni1-x Fe x . There is a small spin-disordered fraction that is typically seen in nanoscale ferromagnets and is likely to be caused by the surface of the nanofibers. There was an additional magnetic contribution that could possibly stem from a small Fe1-z Ni z O phase fraction surrounding the fibers. The coercivity was found to be enhanced when compared with the bulk material.

Modelling the radioluminescence of Sm2+ and Sm3+ in the dosimeter material NaMgF3:Sm.

Photoluminescence (PL) and radioluminescence (RL) measurements were made on NaMgF3:Sm before, during and after exposure to high doses of ionising radiation. Magnetic measurements prior to irradiation showed that approximately 10% of the total Sm concentration was in the divalent state. The RL from Sm3+ was found to increase while the Sm2+ RL decreased with increasing x-ray dose before reaching steady-state values for high doses. This behaviour is opposite to that previously reported for Sm3+ and Sm2+ PL. We show that this apparent discrepancy can be accounted for by a RL model where there is a hole trap, an electron trap, and direct x-ray induced carrier recombination at Sm2+ and Sm3+. Furthermore, a good fit to the dose-dependence of all of the Sm RL emissions can be obtained by assuming that the relevant electron and hole traps are close to Sm3+. Our model accounts for F3-centre production during irradiation that affects some of the Sm3+ RL emissions via reabsorption of the RL by the F3-centres. Thus, the rate of F3-centre production can be conveniently monitored by the RL intensity ratio, I RL(567 nm)/I RL(650 nm). Additionally, the Sm2+ RL emissions may be expressed as [1.94 × I RL(721 nm)] - I RL(695 nm) to determine the real-time dose rate, independent of dose history.

Unusual 209Bi NMR quadrupole effects in topological insulator Bi2Se3.

Three-dimensional topological insulators are an important class of modern materials, and a strong spin-orbit coupling is involved in making the bulk electronic states very different from those near the surface. Bi2Se3 is a model compound, and 209Bi NMR is employed here to investigate the bulk properties of the material with focus on the quadrupole splitting. It will be shown that this splitting measures the energy band inversion induced by spin-orbit coupling in quantitative agreement with first-principle calculations. Furthermore, this quadrupole interaction is very unusual as it can show essentially no angular dependence, e.g., even at the magic angle the first-order splitting remains. Therefore, it is proposed that the magnetic field direction is involved in setting the quantization axis for the electrons, and that their life time leads to a new electronically driven relaxation mechanism, in particular for quadrupolar nuclei like 209Bi. While a quantitative understanding of these effects cannot be given, the results implicate that NMR can become a powerful tool for the investigation of such systems.

Enhanced Power Factor and Increased Conductivity of Aluminum Doped Zinc Oxide Thin Films for Thermoelectric Applications.

We report the structural, electrical and thermopower properties of un-doped and Al doped zinc oxide (ZnO) thin films. Al doping was carried out using 25 keV Al+ implantation with 0.1, 1 and 2% Al into ZnO. X-ray diffraction measurements showed that the lattice parameters were larger than the bulk values, which is consistent with the incorporation of Al atoms at interstitials. Al doping increased the electrical conductivity from 100 (Ωcm)-1 in the un-doped ZnO film to 598 (Ωcm)-1 in the 2% Al doped ZnO film. Electron doping by Al resulted in an increase in the carrier concentration and it had an advantageous effect on the mobility where it was highest for 2% doping. The absolute value of the Seebeck coefficient systematically increased for un-doped, 1% and 2% Al doped ZnO films where the room temperature values were -50.8, -60.9 and -66.3 µV/K, respectively. The power factor increased significantly from 2.58 × 10-5 W/mK2 in un-doped ZnO film to 2.63 × 10-4 W/mK2 in 2% Al doped ZnO film. Our results suggest that the ion beam method is a suitable technique to enhance the thermoelectric properties of ZnO.

Non-publication and publication bias in reproductive medicine: a cohort analysis.

STUDY QUESTION: Does publication bias or non-publication exist in fertility trials presented as conference abstracts? SUMMARY ANSWER: This study did not detect any publication bias; however, it did identify a high level of non-publication, with only 49% of abstracts reaching full-text publication four or more years after abstract presentation. WHAT IS KNOWN ALREADY: Systematic reviews of randomized controlled trials (RCTs) are the foundation of evidence based medicine. Non-publication or publication deficit refer to the failure to publish trial results. A publication bias exists when there is any tendency on the parts of the investigators or editors to fail to publish study results on the basis or strength of the study findings. Both present a serious problem for researchers, clinicians and policymakers alike, and ultimately impact on patient care. STUDY DESIGN, SIZE, DURATION: A retrospective cohort study identified 337 fertility RCTs presented as conference abstracts between 2007 and 2010, as captured by an electronic search of the Cochrane Gynaecology and Fertility Database. After excluding ineligible trials and duplicates, 224 abstracts remained. PARTICIPANTS/MATERIALS, SETTING, METHODS: A search for the full-text papers of each abstract was undertaken in Pubmed, MEDLINE, Embase, CINAHL and Google in May 2015 using a probabilistic approach. Trial authors were contacted to query the publication status of abstracts when no full-text was identified. The association between individual variables and the probability of publication, and time to publication, was assessed using logistic regression and Cox regression, respectively. MAIN RESULTS AND THE ROLE OF CHANCE: Of the 224 included abstracts, only 110 (49%; 95% CI: 42.6, 55.6) were found to be published as full-text articles. Publication bias was not identified in this cohort; studies with positive results had a similar probability of reaching full-text publication 52/113 (46%; 95% CI: 37.0, 55.3) as studies with non-positive (negative or null) results 58/111 (52%; 95% CI: 17.8, 33.9) (adjusted odds ratio (AOR): 1.02; 95% CI: 0.53, 1.97). Similarly, the time from abstract presentation to full-text publication was similar in studies with positive and non-positive results. Oral presentations were more likely to be published, and to be published sooner, than poster presentations (poster presentation AOR: 0.31; 95% CI: 0.15, 0.61 and adjusted hazard ratio (AHR): 0.57; 95% CI: 0.38, 0.86). Studies that were not registered were less likely to be published and to have delayed publication, than studies which were registered either prospectively or retrospectively (AOR: 0.14; 95% CI: 0.04, 0.44 and AHR: 0.43; 95% CI: 0.25, 0.72). Abstracts which were presented a longer time ago also had a higher probability of reaching full-text publication (P  = 0.01). LIMITATIONS, REASONS FOR CAUTION: Commencing with a cohort of RCTs from ethics committee registers may provide a better picture of the extent of non-publication and publication bias, as not all trials reach the stage of abstract presentation. It is also possible that the search did not identify all published trials, as some may have been published after the follow-up period. WIDER IMPLICATIONS OF THE FINDINGS: This study did not identify any publication bias. However, only half of the abstracts in this cohort have been published as full-text articles, four or more years after their presentation at a conference. This is similar to publication rates reported previously for fertility trials, and is despite increasing awareness of the importance of publishing trial results, and subsequent requirements for all RCTs to be registered prior to trial initiation. A better understanding of the reasons for non-publication should assist in facilitating the prompt full-text publication of RCTs in the future. STUDY FUNDING/COMPETING INTEREST(S): Funding provided from the University of Auckland. All authors declare they have no conflicts of interest in relation to this article. TRIAL REGISTRATION NUMBER: Not applicable.

Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.

PURPOSE: This non-randomized, patient-access protocol, assessed both safety and efficacy outcomes following liposomal muramyl-tripeptide-phosphatidylethanolamine (L-MTP-PE; mifamurtide) in patients with high-risk, recurrent and/or metastatic osteosarcoma. METHODS: Patients received mifamurtide 2 mg/m(2) intravenously twice-weekly ×12 weeks, then weekly ×24 weeks with and without chemotherapy. Serum concentration-time profiles were collected. Adverse events within 24 hours of drug administration were classified as infusion-related adverse events (IRAE); other AEs and overall survival (OS) were assessed. RESULTS: The study began therapy in January 2008; the last patient completed therapy in October 2012. Two hundred five patients were enrolled; median age was 16.0 years and 146/205 (71%) had active disease. Mifamurtide serum concentrations declined rapidly in the first 30 minutes post-infusion, then in a log-linear manner 2-6 hours post-dose; t1/2 was 2 hours. There were no readily apparent relationships between age and BSA-normalized clearance, half-life, or pharmacodynamic effects, supporting the dose of 2 mg/m(2) mifamurtide across the age range. Patients reported 3,679 IRAE after 7,482 mifamurtide infusions. These were very rarely grade 3 or 4 and most commonly included chills + fever or headache + fatigue symptom clusters. One- and 2-year OS was 71.7% and 45.9%. Patients with initial metastatic disease or progression approximated by within 9 months of diagnosis (N = 40) had similar 2-year OS (39.9%) as the entire cohort (45.9%) CONCLUSIONS: Mifamurtide had a manageable safety profile; PK/PD of mifamurtide in this patient access study was consistent with prior studies. Two-year OS was 45.9%. A randomized clinical trial would be required to definitively determine impact on patient outcomes.

75As NMR study of overdoped CeFeAsO0.8F0.2.

We report on the results from a (75)As nuclear magnetic resonance (NMR) study of the overdoped iron pnictide superconductor CeFeAsO0.8F0.2. We find two As sites with different shifts at temperatures as high as 100 K, which is above the superconducting transition temperature of 39 K, and hence they cannot be attributed to the effect of vortices in the superconducting state as previously suggested (Ghoshray et al 2009 Phys. Rev. B 79 144512). The much larger spin-lattice relaxation rate compared with that found in other pnictides without magnetic rare earth ions, and the temperature dependence of the (75)As NMR shifts for the two central lines, are consistent with the hyperfine coupling from magnetic Ce to As. The low temperature spectra indicate that there are As ions with two different quadrupole splittings. Our findings appear to be consistent with an electronic phase segregation into regions with two different F dopings or the presence of a correlated spatial charge and spin density variations.

A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.

This Phase I study of clofarabine with etoposide and cyclophosphamide for children with relapsed/refractory acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML) was conducted to determine the maximum tolerated dose (MTD), dose-limiting toxicities and the recommended phase 2 doses (RP2Ds). All three drugs were administered for five consecutive days in induction and four consecutive days in consolidation, for a maximum of eight cycles. A total of 25 patients (20 ALL and 5 AML) were enrolled in five cohorts. An MTD was not reached. The RP2Ds of clofarabine, cyclophosphamide and etoposide were 40, 440 and 100 mg/m(2)/day, respectively. Complete remission (CR) was achieved in 10 patients (ALL: nine; AML: one), and CR without platelet recovery in six patients (ALL: two; AML: four) for an overall response rate of 64% (ALL: 55%; AML: 100%). Of the 16 responders, 9 patients proceeded to hematopoietic stem cell transplantation. In conclusion, the combination of clofarabine, etoposide and cyclophosphamide was well tolerated and effective in pediatric patients with relapsed/refractory leukemia. Of note, the phase II portion of the trial was amended after the occurrence of unexpected hepatotoxicity. The ongoing phase II study will evaluate the efficacy and safety of this regimen in ALL patients.

Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants.

SUMMARY: Treatment of adult ovariectomized (OVX) rats with strontium ranelate prevented vertebral biomechanics degradation as a result of the prevention of bone loss and micro-architecture deterioration associated to an effect on intrinsic bone material quality. Strontium ranelate influenced the determinants of bone strength by prevention of ovariectomy-induced changes which contribute to explain strontium ranelate antifracture efficacy. INTRODUCTION: Strontium ranelate effects on the determinants of bone strength in OVX rats were evaluated. METHODS: Adult female Sprague-Dawley rats were OVX, then treated daily for 52 weeks with 125, 250, or 625 mg strontium ranelate/kg. Bone strength, mass, micro-architecture, turnover, and intrinsic quality were assessed. RESULTS: Strontium ranelate prevented ovariectomy-induced deterioration in mechanical properties with energy necessary for fracture completely maintained vs. SHAM at 625 mg/kg/day, which corresponds to the clinical dose. This was related to a dose-dependent effect on bone volume, higher trabeculae number, and lower trabecular separation in strontium ranelate vs. OVX. Load and energy required to induce lamella deformation were higher with strontium ranelate than in OVX and in SHAM, indicating that the bone formed with strontium ranelate is able to withstand greater damage before fracture. Bone formation was maintained high or even increased in strontium ranelate as shown by mineralizing surfaces and alkaline phosphatase while strontium ranelate led to reductions in deoxypyridinoline. CONCLUSION: Strontium ranelate administered at 625 mg/kg/day for 52 weeks prevented OVX-induced biomechanical properties deterioration by influencing the determinants of bone strength: it prevented bone loss and micro-architecture degradation in association with an effect on intrinsic bone quality. These beneficial effects on bone contribute to explain strontium ranelate antifracture efficacy.

Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic rats.

AIMS: Previous studies have indicated that impaired bone mineralization in 5/6 th nephrectomized rats given high doses of lanthanum carbonate is due to phosphorus depletion caused by excessive binding to, and reduced absorption of, dietary phosphate. This study aimed to test this hypothesis by: 1) directly comparing the effects of a supratherapeutic dose of lanthanum carbonate or dietary phosphorus restriction on bone mineralization in a rodent model of chronic renal failure (CRF); and 2) investigating whether phosphorus supplementation would prevent the bone mineralization defect associated with lanthanum carbonate treatment. METHODS AND MATERIALS: Male Sprague-Dawley rats were subjected to sham surgery or a two-step 5/6th nephrectomy to induce CRF and randomized across five treatment groups: sham, CRF, CRF + dietary phosphorus deficiency, CRF + lanthanum carbonate (1000 mg/kg/ day), and CRF + lanthanum carbonate + parenteral phosphorus repletion. RESULTS: Rats with 5/6th nephrectomy had elevated serum creatinine, blood urea concentration, and urine volume and protein, consistent with impaired renal function, and increased urinary phosphorus and serum parathyroid hormone, consistent with hyperparathyroidism. Lanthanum carbonate and dietary phosphate insufficiency induced parallel changes in serum and urine markers of phosphate homeostasis and increased osteoid formation. These changes induced by lanthanum carbonate were normalized by systemic phosphate supplementation. CONCLUSIONS: These findings provide further support for the concept that supratherapeutic doses of lanthanum carbonate induce effects on bone mineralization in uremic rats via an indirect pharmacological mechanism (phosphate depletion) and not via direct bone toxicity.

Layered tungsten oxide-based organic-inorganic hybrid materials: an infrared and Raman study.

Tungsten oxide-organic layered hybrid materials have been studied by infrared and Raman spectroscopy and demonstrate a difference in bonding nature as the length of the interlayer organic "spacer" molecule is increased. Ethylenediamine-tungsten oxide clearly displays a lack of terminal -NH3(+) ammonium groups which appear in hybrids with longer organic molecules, thus indicating that the longer chains are bound by electrostatic interactions as well as or in place of the hydrogen bonding that must be present in the shorter chain ethylenediamine hybrids. The presence of organic molecules between the tungsten oxide layers, compared with the layered tungstic acid H2WO4, shows a decrease in the apical W=O bond strength, as might be expected from the aforementioned electrostatic interaction.

Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial.

The recombinant urate oxidase, rasburicase (Elitek, Sanofi-Synthelabo, Inc.), has recently received regulatory approval for the prevention and treatment of hyperuricemia in children with leukemia, lymphoma, and solid tumors. Prior to approval, 682 children and 387 adults in the US and Canada received rasburicase on compassionate-use basis. Uric acid concentration declined rapidly in both adult and pediatric patients after rasburicase treatment. Similar responses were observed in patients treated with subsequent courses. Possible drug-related adverse events, including allergic reactions, were uncommon. These data confirm that rasburicase is effective and safe for the treatment and prophylaxis of children and adults with malignancy-associated hyperuricemia.

Alfacalcidol prevents age-related bone loss and causes an atypical pattern of bone formation in aged male rats.

The current study was designed to investigate the skeletal effects of alfacalcidol in aged rats. Eighteen-month-old male rats were treated with 0, 0.1, or 0.2 microg/kg/d of alfacalcidol by daily oral gavage, 5 days/week for 12 weeks. At the beginning of the treatments, one group of rats was euthanized to serve as a baseline control. At the end of the study, the second lumbar vertebrae and the right tibial diaphysess were processed for bone histomorphometric analysis. The fourth lumbar vertebrae were subjected to strength testing. The control group of rats at 21 months of age had decreased serum testosterone levels and decreased cancellous bone mass associated with increased bone turnover on the trabecular surface. The older rats had increased bone turnover on the endocortical surface and decreased bone formation on the periosteal surface compared with the 18-month group. In contrast, alfacalcidol treatment increased cancellous and cortical bone mass in aged male rats. Trabecular bone resorption was decreased whereas bone formation was maintained or increased in the rats treated with alfacalcidol. In addition, endocortical bone formation was decreased whereas periosteal bone formation was increased in the rats treated with alfacalcidol compared with vehicle-treated rats. Marrow trabecular bone area was increased by alfacalcidol treatment in tibial diaphyses. Furthermore, bone strength of the lumbar vertebral body was increased after alfacalcidol treatment. An atypical pattern of bone formation on endosteal bone surfaces was seen in the rats treated with alfacalcidol. The atypical bone formation is characterized by small, focal packets of newly formed bone on trabecular and endocortical bone surfaces. This gave the appearance of the formation of "bone buds" emanating from trabecular surfaces. These bony outgrowths were mineralized and demonstrated significant fluorochrome label indicating recent mineralization. Also, lamellae of the bony buds did not run parallel to those of the trabecular plate to which they are attached. Arrest lines presented in most of the "bone buds". In summary, alfacalcidol treatment increased cancellous and cortical bone mass and improved bone strength, resulting in the prevention of age-related bone loss in aged male rats. An atypical pattern of bone formation observed in this study may be a result of minimodeling based bone formation stimulated by alfacalcidol treatment.

Osteoblast-specific targeting of soluble colony-stimulating factor-1 increases cortical bone thickness in mice.

UNLABELLED: The soluble and membrane-bound forms of CSF-1 are synthesized by osteoblasts and stromal cells in the bone microenvironment. Transgenic mice, generated to selectively express sCSF-1 in bone, showed increased cortical thickness in the femoral diaphysis caused by new bone formation along the endosteal surface. The ability of sCSF-1 to enhance bone cell activity in vivo is potentially relevant for increasing cortical bone in a variety of disorders. INTRODUCTION: The soluble form of colony-stimulating factor-1 (sCSF-1) and the membrane-bound form of CSF-1 (mCSF-1) have been shown to support osteoclastogenesis in vitro; however, the effect of each peptide on bone remodeling in vivo is unclear. To determine the effect of sCSF-1, selectively expressed in bone, the skeletal phenotype of transgenic mice harboring the human sCSF-1 cDNA under the control of the osteocalcin promoter was assessed. METHODS: At 5 and 14 weeks, mice were analyzed for CSF-1 protein levels, weighed, and X-rayed, and femurs were removed for peripheral quantitative computed tomography, histology, and histomorphometry. RESULTS: High levels of human sCSF-1 were detected in bone extracts and, to a lesser extent, in plasma. Adult transgenic mice showed normal body weight and increased circulating monocytic cells. At 5 weeks, the femoral diaphysis was similar in CSF-1T and wt/wt littermates. However, by 14 weeks, the femoral diaphysis in CSF-1T mice showed increased cortical thickness and bone mineral density. In contrast to the diaphysis, the femoral metaphysis of CSF-1T mice showed normal cancellous bone comparable with wt/wt littermates at each time point. Histological sections demonstrated increased woven bone along the endosteal surface of the diaphysis and intracortical remodeling. Fluorochrome-labeling analysis confirmed endocortical bone formation in CSF-1T, with a 3.1-fold increase in the percentage of double-labeled surfaces and a 3.6-fold increase in the bone formation rate compared with wt/wt mice. Although remodeling resulted in a slightly porous cortex, sCSF-1 preferentially stimulated endocortical bone formation, leading to increased cortical thickness. CONCLUSIONS: These findings indicate that sCSF-1 is a key determinant of bone cell activity in the corticoendosteal envelope.

Reinforcement learning for high-level fuzzy Petri nets.

The author has developed a reinforcement learning algorithm for the high-level fuzzy Petri net (HLFPN) models in order to perform structure and parameter learning simultaneously. In addition to the HLFPN itself, the difference and similarity among a variety of subclasses concerning Petri nets are also discussed. As compared with the fuzzy adaptive learning control network (FALCON), the HLFPN model preserves the advantages that: 1) it offers more flexible learning capability because it is able to model both IF-THEN and IF-THEN-ELSE rules; 2) it allows multiple heterogeneous outputs to be drawn if they exist; 3) it offers a more compact data structure for fuzzy production rules so as to save information storage; and 4) it is able to learn faster due to its structural reduction. Finally, main results are presented in the form of seven propositions and supported by some experiments.

Rescue of the osteopetrotic defect in op/op mice by osteoblast-specific targeting of soluble colony-stimulating factor-1.

Soluble colony-stimulating factor-1 (sCSF-1) and membrane bound CSF-1 are synthesized by osteoblasts and stromal cells. However, the precise role of each form in osteoclastogenesis is unclear. In the op/op mouse, absence of osteoblast-derived CSF-1 leads to decreased osteoclasts and osteopetrosis. To determine whether sCSF-1 gene replacement can cure the osteopetrotic defect, we took advantage of the osteoblast specificity of the osteocalcin promoter to selectively express sCSF-1 in the bone of op/op mice. Transgenic mice harboring the human sCSF-1 cDNA under the control of the osteocalcin promoter were generated and cross-bred with heterozygous op/wt mice to establish op/op mutants expressing the transgene (op/opT). The op/op genotype and transgene expression were confirmed by PCR and Southern blot analysis, respectively. High levels of human sCSF-1 protein were selectively expressed in bone. At 2(1/2) wk, op/opT mice showed normal growth and tooth eruption. Femurs removed at 5 and 14 wk were analyzed by peripheral quantitative computed tomography and histomorphometry. The abnormal bone mineral density, cancellous bone volume, and growth plate width observed in op/op mice was completely reversed in op/opT mice by 5 wk, and this effect persisted at 14 wk, with measurements comparable with wt/wt mice at each time point. Correction of the skeletal abnormalities in the 5-wk-old op/opT mice correlated with a marked increase in the total osteoclast number, and their number per millimeter of bone surface compared with that of op/op mutants. Osteoclast number was maintained at 14 wk in op/opT mice and morphologically resembled wt/wt osteoclasts. These results indicate that sCSF-1 is sufficient to drive normal osteoclast development and that the osteocalcin promoter provides an efficient tool for delivery of exogenous genes to the bone. Moreover, targeting sCSF-1 to osteoblasts in the bone microenvironment may be a potentially useful therapeutic modality for treating bone disorders.